Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Crosses Below 200 Day Moving Average of $58.09

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $58.09 and traded as low as $51.02. Enanta Pharmaceuticals shares last traded at $52.65, with a volume of 164,027 shares traded.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ENTA shares. Oppenheimer raised their price objective on Enanta Pharmaceuticals from $53.00 to $59.00 and gave the stock a “market perform” rating in a research note on Wednesday, August 10th. SVB Leerink raised their price objective on Enanta Pharmaceuticals from $44.00 to $50.00 and gave the stock a “market perform” rating in a research note on Monday, August 1st. Evercore ISI raised Enanta Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $62.00 price objective for the company in a research note on Wednesday, July 6th. JMP Securities raised their price objective on Enanta Pharmaceuticals from $103.00 to $137.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 9th. Finally, StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 10th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $78.63.

Enanta Pharmaceuticals Stock Down 0.1 %

The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -8.98 and a beta of 0.55. The company has a 50-day moving average price of $60.55 and a 200 day moving average price of $58.09.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last released its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.17). The firm had revenue of $19.48 million for the quarter, compared to analyst estimates of $20.73 million. Enanta Pharmaceuticals had a negative net margin of 134.21% and a negative return on equity of 32.42%. Enanta Pharmaceuticals’s revenue for the quarter was down 9.9% on a year-over-year basis. During the same period in the previous year, the business posted ($1.19) EPS. Equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -5.75 EPS for the current year.

Institutional Trading of Enanta Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. KBC Group NV acquired a new stake in Enanta Pharmaceuticals during the first quarter valued at $113,000. Point72 Hong Kong Ltd bought a new position in Enanta Pharmaceuticals during the fourth quarter valued at about $114,000. Deep Track Capital LP bought a new position in Enanta Pharmaceuticals during the first quarter valued at about $14,146,000. Walleye Capital LLC bought a new position in Enanta Pharmaceuticals during the fourth quarter valued at about $2,184,000. Finally, DekaBank Deutsche Girozentrale raised its holdings in Enanta Pharmaceuticals by 11.3% during the first quarter. DekaBank Deutsche Girozentrale now owns 3,950 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 400 shares in the last quarter. Institutional investors and hedge funds own 97.09% of the company’s stock.

Enanta Pharmaceuticals Company Profile

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Featured Articles

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.